Kala Pharmaceuticals Announces Proposed Public Offering of Common Stock. The firm had revenue of $1.07 million for the quarter, compared to the consensus estimate of $2.49 million. KALA's price/sales ratio is 89.39; … Copyright © 2020 MarketWatch, Inc. All rights reserved. at $5.21 per share.Derivative/Non-derivative trans.
This change led market cap to move at 571.44M, putting the price 200.00% below the 52-week high and -33.79% above the 52-week low. The most recent insider trade was by Bazemore Todd, Chief Operating Officer, and it was the purchase of 10000.0 shares on Mar 16. The Company granted stock options to purchase up to an aggregate of 21,800 shares of Kala Pharmaceuticals common stock to six new employees. ]In a report issued on May 8, Liana Moussatos from Wedbush maintained a Buy rating on Kala Pharmaceuticals (KALA), with a price target ...[...]There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kala Pharmaceuticals (KALA) and Cytokinetics ...[...]Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2020 Results - Earnings Call TranscriptKala Pharma (KALA) delivered earnings and revenue surprises of -5.88% and -57.02%, respectively, for the quarter ended March 2020. Log in to see them here or sign up to get started.Create a list of the investments you want to track.Visit a quote page and your recently viewed tickers will be displayed here.Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Coca-Cola launching Topo Chico Hard Seltzer as brands from Sam Adams parent and Molson Coors soar
Coronavirus update: U.S. death toll climbs toward 150,000, as COVID-19 enters ‘dangerous new phase’ On March 14, 2019, Jefferies Initiated a Buy rating and boosted its amount on this stock to $15.In the past 52 weeks of trading, this stock has oscillated between a low of $3.24 and a peak of $14.68. at $2.3 per share.Derivative/Non-derivative trans. Lindbrook Capital LLC cut its stake in shares of Kala Pharmaceuticals Inc (NASDAQ:KALA) by 62.2% during the second quarter, according to its most recent disclosure with the SEC. But as of 1st resistance point, this stock is sitting at 10.08 and at 10.44 for 2nd resistance point.Kala Pharmaceuticals Inc. [KALA] reported its earnings at -$0.54 per share in the fiscal quarter closing of 3/30/2020. at $2.3 per share.Derivative/Non-derivative trans.
Kala Pharmaceuticals to Report Second Quarter 2020 Financial Results and Host Conference Call. Get the latest KALA PHARMACEUTICALS INC KALA P (0JQ2.L) stock news and headlines to help you in your trading and investment decisions. As of now, the company’s stock is sitting at 9.50 points at 1st support level, the second support level is making up to 9.28. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Watertown, MA. KALA | Complete Kala Pharmaceuticals Inc. stock news by MarketWatch. Kala Pharmaceuticals last issued its earnings data on May 7th, 2020.
{"OrganizationDocuments":[{"Documents":[{"document":[{"reportDateGroup":[{"reportDate":"2011-06-09","tradeTypeGroup":[{"numTransactions":"5","tradeType":"A"}]},{"reportDate":"2011-05-17","tradeTypeGroup":[{"numTransactions":"3","tradeType":"D"},{"numTransactions":"1","tradeType":"A"}]},{"reportDate":"2011-05-16","tradeTypeGroup":[{"numTransactions":"2","tradeType":"D"},{"numTransactions":"8","tradeType":"A"}]},{"reportDate":"2011-05-13","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-12","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-11","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-02","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-03-10","tradeTypeGroup":[{"numTransactions":"5","tradeType":"A"}]},{"reportDate":"2011-02-17","tradeTypeGroup":[{"numTransactions":"4","tradeType":"D"},{"numTransactions":"2","tradeType":"A"}]},{"reportDate":"2011-02-15","tradeTypeGroup":[{"numTransactions":"8","tradeType":"A"},{"numTransactions":"1","tradeType":"D"}]}]}]}]}]}Derivative/Non-derivative trans. Kala Pharmaceuticals Inc. company facts, information and stock details by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report second quarter 2020 financial results on Thursday, August 6, 2020. Find the latest news headlines from Kala Pharmaceuticals, Inc. Common Stock (KALA) at Nasdaq.com. at $2.3 per share.Derivative/Non-derivative trans. It shows enduring liability to the whole principal at 76.30 and enduring liability to assets at 0.65 while looking for an extended time period.Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock.
Now if looking for a valuation of this stock’s amount to sales ratio it’s 20.78 and it’s amount to book ratio is 4.48.Shifting our attention to insider trading activity, in the last 3 months, 16 insider purchases representing 315,938 shares. Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology.